Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

429
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
429

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Detection of <sub>OXA-23</sub> Among Carbapenem-Resistant Acinetobacter baumannii Isolated From Intensive Care Units of a Tertiary Care Hospital in Pakistan.

MicrobiologyOpen·2026
Same author

A Tissue-Homologous Keratin-PBA Hydrogel Integrating Rationally Designed Nanomicelles Enables Microenvironment-Adaptive Repair of Chronic Diabetic Wounds.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same author

Myopericarditis Secondary to Toxoplasma Gondii Infection in an Immunocompetent Young Male-A Case Report.

Reports (MDPI)·2026
Same author

Trapped Fourth Ventricle in a Pediatric Patient With a History of Post-Traumatic Hydrocephalus and Ventriculoperitoneal Shunt: A Case Report and Literature Review.

Clinical case reports·2026
Same author

Longitudinal Trends and Outcomes in Transcatheter Aortic Valve Implantation: a report from the SwissTAVI Registry.

Cardiovascular intervention and therapeutics·2026
Same author

Histiocytic Sarcoma of Palatine Tonsil in a Pediatric Patient: A Case Report of a Rare and Aggressive Malignancy.

Clinical case reports·2026

Related Experiment Video

Updated: Jul 1, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.2K

Does renal denervation require cardiovascular outcome-driven data?

Syedah Aleena Haider1,2, Max Wagener3, Talha Iqbal4

  • 1Department of Cardiology, University Hospital Galway, Galway, Ireland. ahaider93@hotmail.com.

Hypertension Research : Official Journal of the Japanese Society of Hypertension
|March 11, 2024
PubMed
Summary

Renal denervation (RDN) effectively lowers blood pressure compared to sham procedures. Analyzing trial data suggests blood pressure reduction is a sufficient surrogate for cardiovascular outcomes, simplifying hypertension treatment research.

Keywords:
Antihypertensive agentsHypertensionSympathectomyTreatment outcome

More Related Videos

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.3K
Novel Approach for Simultaneous Recording of Renal Sympathetic Nerve Activity and Blood Pressure with Intravenous Infusion in Conscious, Unrestrained Mice.
11:08

Novel Approach for Simultaneous Recording of Renal Sympathetic Nerve Activity and Blood Pressure with Intravenous Infusion in Conscious, Unrestrained Mice.

Published on: February 14, 2018

10.2K

Related Experiment Videos

Last Updated: Jul 1, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.2K
Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.3K
Novel Approach for Simultaneous Recording of Renal Sympathetic Nerve Activity and Blood Pressure with Intravenous Infusion in Conscious, Unrestrained Mice.
11:08

Novel Approach for Simultaneous Recording of Renal Sympathetic Nerve Activity and Blood Pressure with Intravenous Infusion in Conscious, Unrestrained Mice.

Published on: February 14, 2018

10.2K

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Nephrology

Background:

  • Hypertension is a global health challenge, driving significant cardiovascular disease.
  • Renal denervation (RDN) has emerged as a potential therapy for blood pressure (BP) control.
  • Recent trials have evaluated RDN's efficacy and safety, with mixed discussions on outcome measures.

Purpose of the Study:

  • To analyze statistical methods in RDN trials regarding endpoint definitions.
  • To determine the necessity of major adverse cardiovascular events (MACE)-driven trials versus BP reduction as a surrogate endpoint.
  • To provide evidence supporting the use of BP reduction as a valid surrogate for cardiovascular outcomes in RDN research.

Main Methods:

  • Systematic review and analysis of statistical methodologies employed in major sham-controlled randomized controlled trials of RDN.
  • Evaluation of endpoint definitions, focusing on the comparison between BP reduction and MACE as trial outcomes.
  • Statistical assessment of the evidence supporting BP reduction as a surrogate for cardiovascular outcomes.

Main Results:

  • Most sham-controlled RDN trials demonstrate a significant reduction in 24-hour/daytime ambulatory systolic BP compared to control groups.
  • Analysis of statistical methods supports the conclusion that RDN significantly reduces blood pressure versus sham controls.
  • The use of BP reduction as a surrogate endpoint is supported by trial data and practical limitations of MACE-driven trials.

Conclusions:

  • RDN is a proven method for significantly reducing blood pressure in hypertensive patients.
  • Blood pressure reduction serves as a sufficient surrogate endpoint in RDN trials, simplifying outcome assessment.
  • Considering BP as a surrogate endpoint offers advantages for future hypertension research and treatment strategies, especially given the challenges of long-term MACE evaluation.